CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 39 enrolled
Drug / intervention
Doxycycline +1 moredrug
Likely dose
Doxycycline 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01375491
NCT01375491Phase 4Completed
CompareCT.gov

Blockade of Receptor Cleavage in Diabetes Mellitus With an MMP Inhibitor

University of California, San Diego·interventional·Posted Jun 17, 2011·Updated Jan 13, 2020

In Brief

A Phase 4 clinical trial evaluating Doxycycline and Placebo for Type 2 Diabetes and Obesity. Completed, enrolled 39 participants across 1 site.

Detailed Summary

Obesity is a heightened state of inflammation in which production of cytokines and matrix metalloproteinases (MMPs) result in loss of function of insulin receptors and insulin resistance. Doxycycline (DOX) is a potent MMP inhibitor. We hypothesize that DOX will enhance insulin sensitivity and decreases inflammation in obese participants with type 2 diabetes (DM2).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Obesity
CountriesUnited States
CollaboratorsRuth L. Kirschstein National Research Service Award, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Research Resources (NCRR)

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 17, 2011
Enrollment StartOct 1, 2009
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.0 years ago

Interventions

Doxycyclinedrug

generic doxycycline 100mg twice daily

Placeboother

Placebo comparator to doxycycline